Since its founding in 2013, the Big Ten Cancer Research Consortium (Big Ten CRC) has experienced steady growth, guided by a Steering Committee whose members consist of one representative from each institution. Collectively, the group meets regularly to oversee the activities of the consortium and to decide matters of policy. Each year, the committee appoints a chair and a vice-chair.
Peter G. Shields, MD (pictured left), of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) currently serves as Steering Committee chair, and Thomas G. Sors, PhD, of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D), is vice-chair, representing the Purdue University Center for Cancer Research.
Dr. Shields, a thoracic medical oncologist, oversees the scientific research programs and research infrastructure of the OSUCCC-James, which includes more than 330 cancer researchers and their teams from 11 of Ohio State’s 15 colleges. Through his experience, Dr. Shields understands the importance of multi-institution collaboration to meet the needs of cancer patients as well as investigators, many of whom are early in their careers. Read More
October 15, 2021: In this month’s Across the Consortium, the Big Ten Cancer Research Consortium highlights several investigators involved in detecting, decoding, and understanding genetic abnormalities as well as a potential drug target for treating aggressive pancreatic cancer and a tumor cell that may potentially stop tumor cell seeding and block cancer progression in breast cancer. We also feature a married couple at Penn State Cancer Institute that are building a research program using the MRIdian LINAC by Viewray, a Magnetic Res Magnetic Resonance Imaging (MRI)-guided linear accelerator, one of only 18 units currently open in the U.S. Learn about recent appointments, news grants, and more across our member institutions. Read More
October 13, 2021: Muhammad Furqan, MD, a medical oncologist and researcher at the University of Iowa Holden Comprehensive Cancer Center, presented a featured poster highlighting the Big Ten Cancer Research Consortium study BTCRC-LUN15-017 during the IASLC 2021 World Conference on Lung Cancer, held virtually Sept. 8-14. Investigators of the single arm phase Ib/II study of pembrolizumab and Imprime PGG for patients with metastatic non-small cell lung cancer (NSCLC) after progression on first line therapy, found the combination to be safe in patients with locally advanced or metastatic NSCLC. Read More
October 4, 2021: This month, the Big Ten Cancer Research Consortium features our member institution The Cancer Center at Illinois at University of Illinois Urbana-Champaign and Neha Gothe, MA, PhD, associate professor of kinesiology and community health at the University of Illinois Urbana-Champaign, who serves as director of the university’s Exercise Psychology Lab. She is taking her expertise in kinesiology and behavioral psychology to explore the benefits of non-traditional forms of movement, such as yoga, in cancer survivors. Read More
September 16, 2021: In this month’s Across the Consortium, we share exciting innovations developed by cancer researchers at our member institutions, including a wearable temperature sensor that can detect dangerous complications in hospitalized cancer patients and new dual-mechanism estrogen receptor inhibitors that could support the treatment of estrogen receptor-positive and metastatic breast cancers. We also share recent appointments and publications highlighting faculty at member institutions. See what’s new in this issue of Across the Consortium. Read More
September 1, 2021: This month, the Big Ten Cancer Research Consortium features our member institution Rutgers Cancer Institute of New Jersey and Coral Omene, MD, PhD, medical oncologist at Rutgers Cancer Institute and Assistant Professor of Medicine at Rutgers Robert Wood Johnson Medical School. Research Interests and Expertise: Dr. Omene is a medical oncologist with a passion for women’s health who is dedicated to the care of treating and managing a diverse pool of breast cancer patients. She has devoted much of her research toward translating novel laboratory observations into discoveries to better care for breast cancer patients, with a particular focus on triple negative breast cancer (TNBC), which is known to be among the most... Read More
September 1, 2021: While the world continues to focus on the ever-challenging worldwide COVID-19 pandemic, groundbreaking research into potentially practice-changing novel therapies for oncology patients has continued. This year has been one of innovation in unprecedented times, and the field of gastrointestinal cancers has kept pace. As an early phase clinical investigator at Rutgers Cancer Institute of New Jersey, my research focuses on developing novel combinations to treat advanced biliary tract, hepatic, and pancreatic cancers. Unfortunately, the rising incidence of hepatobiliary and pancreatic cancers, coupled with poor outcomes for these patients, continues to be a pressing reminder of our mission as researchers. Read More
August 26, 2021: In this month’s Across the Consortium, cancer investigators, program managers, and administrators share their progress in oncology research and maintaining their excellent standing through NCI-designation and association accreditation. Learn about new tools that may help identify patients who are at high risk of cancer progression and relapse, as well as promising pre-clinical results to treat human estrogen-receptor positive breast cancer and their metastases in bone, brain, liver, and lungs. Also, find out which of our Big Ten Cancer Research Consortium members increased clinical trial enrollment by 167 percent, and minority participation in clinical trials to 56 percent of total enrollment. Read on to discover what’s new across the Big Ten Cancer Research Consortium. Read More
August 24, 2021: Robert Wesolowski, MD, associate professor at The Ohio State University College of Medicine, was recently appointed as co-chair of the Big Ten Cancer Research Consortium’s Correlative Sciences Clinical Trial Working Group (CTWG). He joins fellow co-chair Thomas G. Sors, PhD, Assistant Director of the Purdue Institute of Inflammation, Immunology and Infectious Disease. The group serves as a resource to advise investigators on the correlative aspects of Big Ten CRC studies in development. “As a clinical trialist, this appointment fits my research interests,” said Dr. Wesolowski, a breast cancer medical oncologist at The Ohio State... Read More
Subscribe to the Big Ten CRC Newsletter
X
Facebook
YouTube